Congenital Hyperinsulinism of Infancy (CHI) is a group of rare, inheritable disorders with persistent hypoglycemia due to hyperinsulinemia. CHI is caused by mutations in genes that affect regulation of insulin secretion in β-cells. One such gene is HADH, which encodes short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD), a metabolic enzyme of the fatty acid beta-oxidation pathway. Mutations resulting in SCHAD deficiency cause protein-sensitive CHI and increased systemic levels of some fatty acid oxidation metabolites.

To test the hypothesis that SCHAD-CHI is caused by a specific deficiency of this ubiquitously expressed protein in β-cells we created β-cell-specific SCHAD knock-out (β-SCHADKO) mice by crossing Hadh-floxed animals with mice expressing Cre under the regulation of the Ins1 promoter. Validity of the β-SCHADKO model was confirmed by PCR, Western Blot and immunofluorescence staining of pancreas tissue. Growth and development of β-SCHADKO mice was similar to littermate controls. Plasma glucose in the KOs was significantly reduced in the random fed state (♂ 158 ± 15 vs. 115 ± 28 mg/dL, p=0.0016; ♀ 143 ± 8 vs. 97 ± 19 mg/dL, p<0.0001) and after overnight fasting (♂ 82 ± 14 vs. 56 ± 13 mg/dL, p<0.0002; ♀ 62 ± 7 vs. 42 ± 4 mg/dL, p<0.0001). Insulin and C-peptide levels were elevated in female KOs after overnight fasting (insulin: 0.25 ± 0.15 vs. 0.38 ± 0.21 ng/mL, p=0.0507; C-peptide: 0.15 ± 0.07 vs. 0.26 ± 0.16 ng/mL, p=0.05), but unchanged in the fed state. GSIS and overall glucose homeostasis, as assessed by insulin and glucose tolerance tests, were not significantly altered. Overall, these data indicate that the β-SCHADKO mouse is a suitable model to investigate the hypoglycemic phenotype of underlying SCHAD deficiency.

Disclosure

J. Ludeke: None. K.M. Velasco: None. D.F. De Jesus: None. B.A. Slipp: None. J. Hu: None. S.J. Steine: None. G. Helgeland: None. P. Njølstad: None. R. Kulkarni: None. A. Molven: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.